ELIE PHARMACY: GLP-1 import refusal records

Has FDA refused imports of GLP-1 products from ELIE PHARMACY?

Yes. FDA’s import refusal records list 5 refused shipment lines declared as made by ELIE PHARMACY (Canada) whose FDA product code names semaglutide, from Nov 9, 2023 to May 13, 2024. None of them carries a product code that FDA’s Import Alert 66-80 lists as a GLP-1 API or powder form.

Country
Canada
City in FDA records
Elie
FEI numbers on the lines
3024614519
Refused lines
5
Lines with an Import Alert 66-80 API or powder code
0
Drugs named in the product codes
Semaglutide
Refusal dates
Nov 9, 2023 to May 13, 2024

The declared manufacturer is the firm named on the import entry. A refusal is FDA’s decision on one shipment line; it is not a finding about the firm’s other products.

Import Alert 66-80’s Green List (published Oct 9, 2026) prints a redaction in place of every firm name, so this index cannot say whether ELIE PHARMACY is on it.

Refused shipment lines

FDA refusal chargesShipment ID
May 13, 2024Canada61PCY72 SEMAGLUTIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).799-0072068-2/11/1
Apr 11, 2024Canada61PAL72 SEMAGLUTIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).799-0098258-9/11/1
Nov 9, 2023Canada61PCK72 SEMAGLUTIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).799-7740186-8/11/1
Nov 9, 2023Canada61PCK72 SEMAGLUTIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).799-7740245-2/11/1
Nov 9, 2023Canada61PCK72 SEMAGLUTIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).799-7740608-1/11/1

FDA refusal charges on these lines

A line can carry several charges. Text is FDA’s charge statement, verbatim.

UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).5

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.

5 lines from FDA files read Nov 15, 2026.